Prostate Cancer: Navigating Through the Maze of Market-Relevant Patient Populations
—A Pharmacor Analyst Call from Decision Resources
Based on our Pharmacor Prostate Cancer advisory service, Decision Resources is offering an exclusive analyst call entitled Prostate Cancer: Navigating Through the Maze of Market-Relevant Patient Populations. Because this analyst call will feature major findings, it is ONLY available to purchasers of this Pharmacor advisory service.
Please contact us to learn how you can purchase this Pharmacor advisory service and attend the analyst call.
The prostate cancer drug market is set to experience significant growth over the next decade, with sales of therapies to treat the disease expected to exceed $10 billion in 2020. The launch of nine emerging therapies that span a variety of drug classes will drive this robust growth. Decision Resources’ analysis of the prostate cancer drug market provides clinically and commercially relevant drug-treatable populations that reflect real clinical scenarios. Definitive primary treatment (such as surgery, radiotherapy and/or hormonal treatment) is fundamental to the management of prostate cancer and response to that treatment is critically important for determining a patient’s clinical state and future treatment. These clinical considerations are integral to the formation of our drug-treatable populations.
With all but one emerging therapy expected to penetrate the metastatic castrate-resistant prostate cancer (mCRPC) setting, this will become an increasingly crowded and competitive space. However, considerable opportunity will remain for therapies entering the mCRPC setting to penetrate more lucrative earlier-stage disease settings.
This 15-minute analyst call, presented by Analyst Rachel Webster, D.Phil., will answer the following questions:
- What are the drug-treatable populations included in our market and how are they defined? How are these commercially relevant patient populations derived and how does patient flow help to formulate these populations?
- In regard to the overall prostate cancer drug market, which drug-treatable populations will be the most lucrative and which hold the most opportunity for developers?
- In which drug-treatable populations does Decision Resources expect key emerging therapies to be positioned in and what will be the market impact of these agents?
Dr. Webster will conduct a live Q & A session after the presentation.
Prostate Cancer: Navigating Through the Maze of Market-Relevant Patient Populations
October 26, 2011 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris).
To learn how you can purchase this Pharmacor advisory service and attend the analyst call, please contact us using the information below.
In North America | Keith Rourke | 781-993-2656
In Europe | Kaj van Langendonck | +32-2-357-06-14
In Japan | Makiko Yoshimoto | +81-3-5401-2615
Webinar Details Date & Time Duration: 15 minutes |
About the Speaker
|
Rachel Webster, M.Sc., D.Phil., is an analyst in the oncology group at Decision Resources. Prior to joining the company, Dr. Webster was a research scientist at Immunocore (formerly MediGene) in the phage display and protein engineering group. Dr. Webster also worked at Cybersense Biosystems, where her research involved molecular engineering of bacterial membrane receptors and signal transduction pathways for the construction of a biosensor. Dr. Webster obtained her D.Phil. and M.Sc. in biological sciences from the University of Oxford.
Terms of Use | Privacy Policy | Contact Us | Careers
Decision Resources • 8 New England Executive Park • Burlington, MA 01803
You are receiving this email because you have previously requested information from Decision Resources. You can update your email preferences at any time.
© 2011 Decision Resources, LLC. All rights reserved.
